Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
CYTOKINETICS INC President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of Common Stock at $77.92 per share. After this transaction, he directly holds 400,330 shares. Separate from his direct position, 2,083 shares are held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held by The Brittany Blum 2003 Irrevocable Trust as indirect holdings.
Cytokinetics, Incorporated entered into an underwriting agreement for a public offering of 9,859,155 shares of its common stock at a public offering price of $71.00 per share.
The underwriters received a 30-day option to buy up to an additional 1,478,873 shares, which they fully exercised on May 7, 2026. After underwriting discounts, commissions and estimated expenses, net proceeds to Cytokinetics from the offering are approximately $760.2 million, providing substantial new capital to the company.
Cytokinetics is offering 9,859,155 shares of common stock. The underwriters have agreed to purchase the shares from the company at $71.00 per share, which will result in approximately $700 million of proceeds to the company before expenses; the company estimates $661.0 million of net proceeds. The underwriters may also purchase up to 1,478,873 additional shares within 30 days from the date of this prospectus supplement. The company states the net proceeds are intended for the commercial launch of MYQORZO, advancing its pipeline and general corporate purposes.
Shares outstanding were 124,237,823 as of March 31, 2026; the pro forma shares outstanding immediately after the offering are stated as 134,096,978. The offering is being conducted under a shelf registration and is subject to customary lock-up agreements, underwriting terms and international selling restrictions.
FMR LLC filed Amendment No. 7 to a Schedule 13G/A reporting beneficial ownership of 11,135,192.23 shares of Cytokinetics Inc. common stock, representing 9.0% of the class as of 03/31/2026. The filing lists sole dispositive power for 11,135,192.23 shares and references a Power of Attorney for signature authority.
Cytokinetics EVP of Research & Development Fady Ibraham Malik exercised stock options and sold the resulting shares. He exercised 3,500 shares of common stock through a non-qualified stock option at $7.80 per share, then completed an open-market sale of 3,500 shares at $77.37 per share on the same date. Following these transactions, he directly held 153,902 shares of Cytokinetics common stock, indicating his overall share count remained broadly stable after the exercise-and-sell sequence.
Cytokinetics EVP of Research & Development Fady Ibraham Malik exercised stock options and sold the resulting shares. He exercised 3,500 shares of common stock through a non-qualified stock option at $7.80 per share, then completed an open-market sale of 3,500 shares at $77.37 per share on the same date. Following these transactions, he directly held 153,902 shares of Cytokinetics common stock, indicating his overall share count remained broadly stable after the exercise-and-sell sequence.
Cytokinetics EVP of Research & Development Fady Ibraham Malik exercised stock options and sold the resulting shares. He exercised 3,500 shares of common stock through a non-qualified stock option at $7.80 per share, then completed an open-market sale of 3,500 shares at $77.37 per share on the same date. Following these transactions, he directly held 153,902 shares of Cytokinetics common stock, indicating his overall share count remained broadly stable after the exercise-and-sell sequence.
Cytokinetics, Incorporated is offering common stock with an aggregate public offering price of $650,000,000 pursuant to this preliminary prospectus supplement dated May 5, 2026. The underwriters have a 30‑day option to purchase additional shares with an aggregate public offering price of up to $97,500,000.
The prospectus supplement uses a shelf registration filed on Form S-3 and states the offering price per share and gross proceeds per share are to be determined in this preliminary document. Shares outstanding were 124,237,823 as of March 31, 2026. Proceeds are intended to fund the commercial launch of MYQORZO, advance the pipeline and for general corporate purposes.
Cytokinetics, Incorporated is offering common stock with an aggregate public offering price of $650,000,000 pursuant to this preliminary prospectus supplement dated May 5, 2026. The underwriters have a 30‑day option to purchase additional shares with an aggregate public offering price of up to $97,500,000.
The prospectus supplement uses a shelf registration filed on Form S-3 and states the offering price per share and gross proceeds per share are to be determined in this preliminary document. Shares outstanding were 124,237,823 as of March 31, 2026. Proceeds are intended to fund the commercial launch of MYQORZO, advance the pipeline and for general corporate purposes.
Cytokinetics, Incorporated is offering common stock with an aggregate public offering price of $650,000,000 pursuant to this preliminary prospectus supplement dated May 5, 2026. The underwriters have a 30‑day option to purchase additional shares with an aggregate public offering price of up to $97,500,000.
The prospectus supplement uses a shelf registration filed on Form S-3 and states the offering price per share and gross proceeds per share are to be determined in this preliminary document. Shares outstanding were 124,237,823 as of March 31, 2026. Proceeds are intended to fund the commercial launch of MYQORZO, advance the pipeline and for general corporate purposes.
Insider filing to sell Common stock. The Form 144 lists 23,906 Common shares tied to restricted stock units and performance stock units dated 12/03/2024. The filing records a prior sale of 4,935 shares on 03/17/2026 for $306,710.25. The broker shown is Morgan Stanley Smith Barney LLC.
Insider filing to sell Common stock. The Form 144 lists 23,906 Common shares tied to restricted stock units and performance stock units dated 12/03/2024. The filing records a prior sale of 4,935 shares on 03/17/2026 for $306,710.25. The broker shown is Morgan Stanley Smith Barney LLC.
Insider filing to sell Common stock. The Form 144 lists 23,906 Common shares tied to restricted stock units and performance stock units dated 12/03/2024. The filing records a prior sale of 4,935 shares on 03/17/2026 for $306,710.25. The broker shown is Morgan Stanley Smith Barney LLC.
Cytokinetics director Wendell Wierenga reported an exercise-and-sell transaction in company stock. He exercised a non-qualified stock option for 4,032 shares of Common Stock at $12.40 per share and on the same date sold 4,032 shares in an open-market trade at $75.00 per share. After these transactions, he directly owns 32,637 shares of Cytokinetics Common Stock, and the option covering 4,032 shares has been fully exercised.
Cytokinetics director Wendell Wierenga reported an exercise-and-sell transaction in company stock. He exercised a non-qualified stock option for 4,032 shares of Common Stock at $12.40 per share and on the same date sold 4,032 shares in an open-market trade at $75.00 per share. After these transactions, he directly owns 32,637 shares of Cytokinetics Common Stock, and the option covering 4,032 shares has been fully exercised.
Cytokinetics director Wendell Wierenga reported an exercise-and-sell transaction in company stock. He exercised a non-qualified stock option for 4,032 shares of Common Stock at $12.40 per share and on the same date sold 4,032 shares in an open-market trade at $75.00 per share. After these transactions, he directly owns 32,637 shares of Cytokinetics Common Stock, and the option covering 4,032 shares has been fully exercised.